Objective:To explore the molecular mechanisms of Purendan superfine powder（PRD）on metabolic disorder and the protection on macroangiopathy by investigating the protein expression of insulin receptor substrate-1（IRS-1）

phosphatidylinositol 3-kinase（PI3K）

glucose transporter 4（GLUT4） and nuclear factor-κB（NF-κB） of skeletal muscles in type 2 diabetes mellitus（T2DM） rats with macroangiopathy.Method: High-fat-diet/streptozotocin（STZ

30 mg · kg-1）-induced type 2 diabetes mellitus rats were developed and treated with PRD（0.885

1.770

3.540 g · kg-1） for four weeks and rosiglitazone（0.36×10-3 g · kg-1） was used as positive control drugs

then western blot assay was used to analyze the protein expression of IRS-1

PI3K

GLUT 4 and NF-κB of skeletal muscle in the rats.Result: The protein expression of IRS-1

PI3K and GLUT-4 was significantly decreased in T2DM group compared with the control group（P<0.01）

while NF-κB expression was significantly increased（P<0.01）.After the treatment of PRD

the expression of IRS-1

PI3K and GLUT-4 was up-regulated

and NF-κB was down-regulated significantly（P<0.05 or P<0.01）

which was equivalent to the positive drugs.Conclusion: PRD could improve insulin resistance

decrease blood glucose and fat

protect the vascular endothelium injury by up-regulating IRS-1

PI-3K and GLUT 4 protein expression and down-regulating NF-κB protein expression of skeletal muscle in T2DM rats.